Nerve Growth Factor
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Musculoskeletal Pain
Conditions
Musculoskeletal Pain
Trial Timeline
Oct 1, 2017 → Jul 1, 2020
NCT ID
NCT04457466About Nerve Growth Factor
Nerve Growth Factor is a pre-clinical stage product being developed by Lundbeck for Musculoskeletal Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT04457466. Target conditions include Musculoskeletal Pain.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04457466 | Pre-clinical | Terminated |
Competing Products
4 competing products in Musculoskeletal Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride | Eisai | Phase 3 | 77 |
| No intervention | Johnson & Johnson | Pre-clinical | 23 |
| ACE-083 | Merck | Phase 1 | 33 |
| Lumiracoxib | Novartis | Approved | 85 |